4.80Open4.00Pre Close2 Volume3 Open Interest10.00Strike Price960.00Turnover106.00%IV0.07%PremiumDec 20, 2024Expiry Date4.79Intrinsic Value100Multiplier30DDays to Expiry0.01Extrinsic Value100Contract SizeAmericanOptions Type0.9250Delta0.0312Gamma2.96Leverage Ratio-0.0115Theta0.0073Rho2.74Eff Leverage0.0061Vega
Grail Stock Discussion
Larger Image: tradingview.com...
$Grail (GRAL.US)$
GRAIL Advances the Galleri® Registrational Clinical Trial Program
GRAIL (NASDAQ: GRAL) has announced significant progress in its clinical trials for the Galleri® multi-cancer early detection (MCED) test. The company has completed enrollment of over 35,000 participants in the PATHFINDER 2 study across North America and finished the final study visits for the NHS-Galleri trial with more than 140,000 participants in England. Results from the first 25,000 PATHFINDER 2 participan...
No comment yet